5results about How to "Increased susceptibility" patented technology

The present invention discloses the application of ubiquitin-binding enzyme UBE2L6 in preventing and treating blue ear disease in pigs and identifying blue ear disease-resistant pigs. The present invention first discovered that after pigs are infected with PRRSV virus, the expression of ubiquitin-binding enzyme E2L6 will be promoted, and the expression level of UBE2L6 will increase significantly with the increase of infection time. At the same time, UBE2L6 gene knockdown promotes PRRSV replication, and UBE2L6 overexpression significantly inhibits virus replication; when the expression level of UBE2L6 in pigs is high, the pigs are resistant to PRRSV, and vice versa. Therefore, promoting UBE2L6 expression can improve pigs' resistance to blue ear virus, and UBE2L6 can be used as a standard for determining PRRSV susceptibility or resistance. The present invention lays a solid foundation for identifying pigs susceptible to PRRSV and resistant pigs by discovering new disease resistance / susceptibility genes of PRRSV hosts, which is conducive to the breeding of excellent strains of pigs and has important significance for the prevention and control of blue ear disease in pigs.

An object of the present invention is to a new method of producing a kidney organoid. The method for producing a kidney organoid is characterized by comprising culturing an early kidney organoid with a medium containing an RXR agonist and a PPAR agonist, wherein the kidney organoid includes matured proximal tubule cells.

The application belongs to the technical field of molecular biology breeding, and particularly relates to application of EF Hand family genes in improving resistance of tomatoes to pathogenic Phytophthora. Two pathogenic Phytophthora disease-related genes are found and verified in tomatoes, the genomic nucleotide sequences of which are shown as SEQ ID NO: 1 and SEQ ID NO: 2 respectively, and the two genes both belong to members of the EF Hand gene family. By knocking out or silencing the above genes through gene editing technology, it is found that the tomato lines with the above genes knocked out or silenced have higher resistance to pathogenic Phytophthora compared with wild types. Meanwhile, the gene-edited tomato lines are not obviously affected in growth and development. Therefore, the application not only enriches the research on pathogenic Phytophthora disease-related genes in tomatoes, but also develops tomato lines with enhanced resistance to pathogenic Phytophthora by using the characteristics of the above genes, thereby providing new technical strategies and gene resources for tomato breeding.

This invention discloses a gene regulating resistance to Huanglongbing (HLB) in citrus. CsXCP2 and its applications, the regulatory genes CsXCP2 The nucleotide sequence is shown in SEQ ID No. 1. The amino acid sequence of the protein CsXCP2 is shown in SEQ ID No. 2. This invention is the first to clone and identify the citrus cysteine ​​protease gene. CsXCP2 The function of [the substance] was revealed, showing that it is an important regulatory hub in the citrus immune signaling pathway and has antibacterial effects. This invention confirms that [the substance]... CsXCP2 By specifically enhancing the activation of the salicylic acid signaling pathway and directly inhibiting the growth of Huanglongbing fungus, citrus fruits are conferred resistance to Huanglongbing. Compared with existing findings, CsXCP2 This provides a new breeding target with a clear mechanism of action and significant disease resistance, which can alleviate the shortcomings of insufficient or limited effectiveness of existing resistance gene resources.

This invention belongs to the field of biomedical technology, specifically relating to a diagnostic agent for the risk of new-onset atrial fibrillation in the elderly and its application. This invention discovers that plasma QUIN expression levels can be used as a quantitative screening standard for the risk of atrial fibrillation in the elderly population. When the QUIN expression level in a subject's biological sample is ≥88.02 ng / mL, the subject has a risk of developing atrial fibrillation within the next 10 years; the higher the QUIN level, the higher the risk. When the QUIN content in a subject's biological sample is ≥215.5 ng / mL and ≥280.4 ng / mL, respectively, the predicted cumulative risk of atrial fibrillation within 3 years is over 90% and over 95%, respectively. This technique of clearly stratifying subjects and quantifying risk assists in individualized intervention and clinical management, providing a reference for precision treatment.